FindTrial
Sign In

2 mg/ml

DRUG3 trials

Sponsors

Odense University Hospital, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A., Friedrich-Schiller-Universitaet Jena, Friedrich-Schiller-Universitaet Jena

Conditions

Advanced dedifferentiated liposarcomaCows' milk allergyGERDPatients with sepsis or septic shockcurrently hospitalized at the Intensive Care Unit (ICU) or Intermediate Care (IMC) regardless where the sepsis was first diagnosed.

Phase 2

Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma
CompletedCTIS2024-511361-11-00
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.Advanced dedifferentiated liposarcoma
Start: 2022-03-25End: 2025-11-21Target: 209Updated: 2025-07-04
Epirubicin for the Treatment of Sepsis & Septic Shock
CompletedCTIS2024-515776-12-00
Friedrich-Schiller-Universitaet Jena, Friedrich-Schiller-Universitaet Jenacurrently hospitalized at the Intensive Care Unit (ICU) or Intermediate Care (IMC) regardless where the sepsis was first diagnosed., Patients with sepsis or septic shock
Start: 2022-06-30End: 2025-05-21Target: 45Updated: 2024-10-01

Phase 3

Behandling af gastroesofageal refluks sygdom hos spædbørn- et randomiseret studie Treatment of Gastroesophageal Reflux Disease in Infants- a Randomized Controlled Trial
RecruitingCTIS2022-502770-16-00
Odense University HospitalCows' milk allergy, GERD
Start: 2025-10-27Target: 96Updated: 2025-03-07

Related Papers

Infant Reflux Trial: study protocol for a multicentre randomized controlled trial on the treatment of gastroesophageal reflux disease in infants
Trials2026-01-29